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Cardiac involvement and presenting dFLC (difference between involved and uninvolved free 
light chains) are independent predictors of outcome in systemic AL amyloidosis. These 
markers have limited prognostic utility in patients surviving the initial months following 
diagnosis. Here we assessed immunoparesis, as determined by novel heavy+light chain 
(HLC) immunoassays, as a prognostic marker for survival in AL amyloidosis. HLC 
measurements identified immunoparesis of at least one immunoglobulin (Ig) isotype in 
145(85%) patients; and severe immunoparesis (≥2 Ig isotypes suppressed by >50% below 
normal levels) in 29(17%) patients. Median overall survival (OS) on intention to treat (ITT) 
analysis was 26.2 months. In the ITT cohort, dFLC >180mg/L was associated with shorter OS 
(p=0.05); whereas HLC immunoparesis was not prognostic. On a landmark analysis of 127 
patients alive at 6 months, presenting dFLC was not prognostic for OS (p=0.33) and severe 
HLC immunoparesis trended towards poorer survival (20.2 vs. 42.8 months; p=0.09). In the 
subset of patients with cardiac involvement, severe HLC immunoparesis conferred very poor 
outcome (median OS 8.8 vs. 29.9 months, p=0.007). In conclusion severe HLC 
immunoparesis is an independent marker of long-term poor prognosis in AL patients with 
cardiac involvement. The pathophysiological significance of this observation needs further 
study.   




Systemic light chain amyloidosis (AL amyloidosis) is a rare disorder of misfolded monoclonal 
immunoglobulin free light chains (FLC), which result in insoluble fibrils deposition in organs 
causing progressive organ dysfunction. The amyloidogenic FLC are products of an underlying 
B cell clonal disorder (usually a plasma cell clone) and current therapeutic strategies are aimed 
at targeting such clones to reduce the levels of circulating clonal FLC.  The prognosis in a 
patient with systemic AL amyloidosis depends on the extent of end organ damage – 
particularly cardiac impairment.  Additionally, the level of circulating FLC also has independent 
prognostic significance (Comenzo, et al 2012, Dispenzieri, et al 2009, Kumar, et al 2012, 
Palladini, et al 2012); as has achieving a deep biochemical response to therapy. A substantial 
proportion of patients (up to 30% in some series) succumb prematurely to disease related 
complications, primarily due to advanced cardiac involvement (Dispenzieri, et al 2004). Hence 
the prognostic factors in the early survivors (i.e. outcomes on landmark analyses) are very 
different from those of ‘intention to treat analysis’ at baseline. The value of current amyloidosis 
staging systems in assessing longer term prognosis of patients surviving past the initial few 
months remains unclear and appears to be limited.   
In addition to free light chains, monoclonal intact immunoglobulins (M-Igs) are also 
expressed in about 50-75% of patients with AL amyloidosis, although only in about 25% of 
patients the levels are measurable for monitoring purposes (Lachmann, et al 2003). The 
prognostic value of an intact M-Ig in systemic AL amyloidosis is unclear, with some series 
reporting poorer outcomes for patients expressing intact immunoglobulins (Kumar, et al 2010, 
Kumar, et al 2011). Alternatively and similar to other plasma cell dyscrasias, systemic 
immunoparesis has recently been associated with poorer outcomes in AL amyloidosis patients 
(Muchtar, et al 2016b).  
Novel serum assays allow quantification of Ig’κ and Ig’λ heavy+light chains (HLC) from 
which Ig’κ / Ig’λ HLC ratios can be derived. This may give an indication of clonality and HLC 
immunoassays appear to be sensitive for identifying and quantifying levels of M-Ig in plasma 
cell dyscrasias (Bijzet, et al 2012, Ludwig, et al 2013, Schonland, et al 2012). The particular 
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advantage of HLC immunoassays over traditional methods of immunoglobulin measurements 
is that it allows the quantification of the uninvolved (non-clonal) member of the pair as well as 
of the other immunoglobulin classes (e.g. in an IgGκ monoclonal protein expressing patient, 
levels of IgGλ, IgAκ, IgAλ, IgMκ and IgMλ may be measured) –thus providing an accurate 
measurement of isotype and non-isotype specific immunoglobulin values as well as pair 
immunosuppression.   
There are few studies evaluating the role of HLC suppression for prognostication in 
plasma cell dyscrasias. In myeloma, HLC suppression appears to predict for poorer outcomes 
(Avet-Loiseau, et al 2011, Harutyunyan, et al 2016, Ludwig, et al 2016).  Here we report the 
significance of immunoparesis as determined by HLC suppression in a population of newly 




The study included unselected patients with AL amyloidosis seen at the National 
Amyloidosis Centre in London between 2003-2008, with serum samples collected at the time 
of presentation, prior to any therapy, and stored at -80°C. A total of 170 patients with systemic 
AL amyloidosis were included. There was no blinding in the study. Diagnosis of amyloidosis 
was confirmed in all cases with a tissue biopsy demonstrating characteristic birefringence on 
Congo red staining. Typing of AL amyloidosis was confirmed by immunohistochemical staining 
with appropriate antibodies and by exclusion of hereditary amyloidosis, where necessary, by 
genetic sequencing of the genes implicated. Patients fulfilling criteria for symptomatic 
myeloma were excluded.  All patients underwent systematic review at presentation and 
detailed follow up assessments at 6 monthly intervals or as clinically indicated.  Assessment 
included clinical examination, detailed blood and urine analysis (including assessment of 
serum and urine monoclonal immunoglobulin and serum free light chains), serial 123I labelled 
serum amyloid P component (SAP) scintigraphy to assess whole body amyloid load, 
electrocardiogram (ECG) and echocardiogram.  Organ involvement was defined according to 
the international amyloidosis consensus criteria (Gertz, et al 2004a). Patients were treated 
with chemotherapy regimens used to treat myeloma during the study period. Treatment 
information was available for 109 (66 %) of the patients. Treatment regimen included those 
based on thalidomide (37%), melphalan (13%), cyclophosphamide (4%) and VAD (2%). 
Serum samples were tested for FLC concentrations (κ sFLC and λ sFLC) using 
Freelite® assays (The Binding Site Group Ltd, UK), HLC concentrations (IgGκ, IgGλ, IgAκ, 
IgAλ, IgMκ and IgMλ) using Hevylite® assays (The Binding Site Group Ltd, UK) and total 
immunoglobulins (IgG, IgA and IgM) on a BNTMII System nephelometer (Siemens, Germany). 
Serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) (Sebia, 
France) were carried out using standard laboratory procedures.  Immunoparesis was defined 
either by total immunoglobulin (Ig) measurements as the concentration of any Ig class below 
the lower limit of normal (i.e. IgG<6 g/L, IgA<0.8 g/L, IgM<0.5 g/L; total Ig suppression), or by 
HLC immunoassays as levels of any IgGκ, IgGλ, IgAκ, IgAλ, IgMκ and/or IgMλ below the lower 
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limit of their respective reference range (HLC suppression; Supplementary Table 1). Moderate 
immunoparesis was defined as at least two Ig isotypes suppressed below the lower limit of 
normal, and severe immunoparesis was defined as levels of two or more isotypes suppressed 
by 50% or greater below the lower limit of normal. 
Survival studies were performed on 163 patients with available follow-up data (median follow 
up 35 months (2.4 – 85.3 months). Cardiac involvement for survival studies was defined as 
above and/or NT-proBNP >332 ng/L. There were 108 deaths of which 8 were due to infection 
and 89 due to amyloidosis. Differences in overall survival (OS) between patient groups were 
analysed using Kaplan-Meier survival curves with the log rank test used to indicate 
significance. The association of variables with OS was performed with Cox proportional hazard 
model. A landmark analysis was carried out in patients surviving 6 months from study entry. p 
values were two-tailed with a significance level of 0.05. Statistical analyses were performed 
using SPSS v21 (IBM, Chicago, USA). Statistical differences for categorical values were 
calculated using the chi-square (2) test. Survival graphs were generated using 
GraphPad/Prism 5 software. 
The study was carried out in accordance with Good Clinical Practice guidelines and 
the Declaration of Helsinki, and was approved by the institutional review board. All 




Baseline characteristics including demographics, clinical features and serum biomarkers for 
170 AL amyloidosis patients are presented in Table 1 – 73% and 63% respectively had cardiac 
and renal involvement. None of the patients had symptomatic myeloma but 21% had greater 
than 10 % bone marrow plasma cell infiltration. The association of baseline variables with 
HLC and total Ig immunoparesis is presented on Table 1; and on supplementary Tables 
2 and 3 for moderate and severe immunoparesis, respectively. Our analyses mainly 
revealed an association between any degree of immunoparesis and an abnormal serum 
/ FLC ratio.  
HLC measurements identified immunosuppression of at least one of any IgGκ, IgGλ, 
IgAκ, IgAλ, IgMκ and IgMλ in 145/170 (85%) patients (Table 2). Specifically, IgGk levels were 
suppressed in 108 (64%) patients, IgGλ in 75 (44%), IgAk in 56 (33%), IgAλ in 42 (25%), IgMk 
in 79 (47%) and IgMλ in 70 (41%).  In addition 80/170 (47%) patients presented with moderate 
HLC immunoparesis. Severe immunoparesis was identified by HLC measurements in 29/170 
(17%) patients (Table 2).   
Total Ig measurements identified immunoparesis of at least one of any IgG, IgA and 
IgM in 115/166 (69%) patients; all of which were identified by HLC suppression. 56/166 (34%) 
patients had two or more immunoglobulins below normal levels, and in 18/166 (11%) patients 
immunoparesis was severe (Table 2).   
We assessed the impact of immunoparesis on survival outcomes. There were 108 
deaths.  Infection was reported as a cause of death in 8 cases.  Other reported causes 
included: acute leukaemia – 1, gastrointestinal bleeding – 2, myocardial infarction – 1, renal 
failure - 3, treatment related - 4 and all remaining cases – progressive amyloidosis or 
amyloidosis. Median survival for this cohort was 26.2 months. In the intent to treat (ITT) cohort, 
presence of more than 1 organ involved, cardiac involvement, abnormal NT-proBNP and 
high monoclonal FLC levels were factors adversely affecting survival by univariate analysis, 
and trended towards significance in multivariate; whereas the presence of an M-protein, 
an abnormal HLC ratio, and immunoparesis by either method had no significant impact on 
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survival (Table 3). Median OS for patients with dFLC levels above or below 180 mg/L was 
14.8 vs. 43.1 months, respectively (Hazard Ratio (HR) (95%CI): 1.6 (1.0-2.4); p=0.05), 
whereas median survival for patients with severe HLC immunoparesis was 14.8 months 
compared to 28.0 months for all other patients (HR: 1.4 (0.9-2.3); p=0.16) (Figure 1A-C). We 
further assessed the survival characteristics of 121 patients who presented with cardiac 
involvement. In multivariate analysis, more than 1 organ affected, dFLC >180 mg/L and 
severe HLC immunoparesis were associated with poorer survival (Table 3). Median OS for 
this cardiac population was 14.8 months. Median OS for dFLC >180 mg/L vs. dFLC <180 mg/L 
was 12.6 and 35.1 months, respectively (HR: 1.7 (1.0-2.9); p=0.04); and severe HLC 
immnoparesis vs. all other patients was 8.8 and 21 months respectively (HR: 1.7 (1.0-2.9); 
p=0.06) (Figure 1D-F). Severe immunoparesis as determined by total Ig measurements had 
no impact on prognosis in cardiac patients (p=0.81; Table 3).  
We carried out a landmark analysis of 127 patients who survived for at least 6 months 
(Table 3 and Figure 2). Median survival for this population was 40.9 months. Cox regression 
and Kaplan-Meier analysis revealed organ involvement and dFLC levels no longer 
associated with outcome in this cohort. There was a suggestion that patients with 
severe HLC suppression had a trend towards poorer survival (p=0.09). Indeed, in 
patients with cardiac involvement, in the 6-month landmark analysis, severe HLC 
suppression (HR: 2.4 (1.2-4.6); p=0.009) was the only variable associated with shorter 
overall survival.  A landmark analysis at nine and twelve months of patients with cardiac 
involvement and HLC suppression also demonstrated association with survival, with median 
OS of 58.5 and 63.7 months for those with mild/no HLC suppression at nine and twelve 
months, respectively, compared to 28.4 months for those with severe HLC suppression 
(p=0.111 and p=0.059 respectively; supplementary Figure 1).  
A tentative survival model including dFLC >180mg/L and severe HLC suppression as 
risk factors in patients with cardiac involvement stratified the population into three categories 
with none (n=49), one (n=59) and two (n=13) risk factors and median survival times of 35.1, 




The impact of immunoparesis on outcomes in plasma cell dyscrasias has been studied and 
debated for many years, but only recently has been specifically assessed in AL amyloidosis. 
Here we report that immunoparesis is common in systemic AL amyloidosis by both standard 
nephelometric immunoglobulin measurements and as determined by HLC immunoassays. 
Our main finding indicates that severe immunoparesis measured by HLC immunoassay, but 
not by total Ig measurements, is a marker of poor prognosis particularly in patients with cardiac 
amyloidosis who survive the first few months after therapy.  
Impact of M-Ig on outcomes in AL amyloidosis is unclear. The Mayo group reported 
that response to treatment as determined by FLC but not by intact M-Ig impacted survival in 
AL, both in chemotherapy and transplant settings (Kumar, et al 2010, Kumar, et al 2011)– data 
which was confirmed by a collaborative study defining response criteria in AL amyloidosis 
(Palladini, et al 2012). The current cohort confirms these findings; where the presence of an 
M-Ig by IFE had no prognostic value. Traditional electrophoretic methods lack sensitivity for 
detecting M-Ig and cannot accurately quantify the low levels typically encountered in patients 
with systemic AL amyloidosis (Harding, et al 2010, Lachmann, et al 2003). HLC 
immunoassays have a greater sensitivity for detection of M-Ig’s and may aid the monitoring 
and prognostication of monoclonal gammopathies (Avet-Loiseau, et al 2009, Katzmann, et al 
2013, Ludwig, et al 2013).  
In patients with multiple myeloma, extreme abnormality of HLC ratio at presentation 
(<0.01 or >200) was associated with shorter time to disease progression in IFM 2005-01MM 
trial patients (Bradwell, et al 2013). It also associates with shorter progression free survival 
and overall survival (Bradwell, et al 2013, Koulieris, et al 2012). The suppression of the 
uninvolved immunoglobulin of the same heavy chain isotype appears to be a major contributor 
to this prognostic impact; it also predicts for shorter time to progression in MGUS (Katzmann, 
et al 2013).  
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Unlike myeloma, extreme HLC ratios are rarely seen in AL amyloidosis. By contrast, 
immunoparesis is nearly universal in myeloma and seen in a proportion of patients with 
monoclonal gammopathy of undetermined significance (MGUS) (Katzmann, et al 2013). 
However, systemic immunoparesis as determined by total Ig measurements remains an 
inconsistent risk factor both in MGUS and MM (Cesana, et al 2002, Kastritis, et al 2014, 
Katzmann, et al 2013, Turesson, et al 2014). We found a greater incidence of HLC 
suppression (85%) over total Ig immunoparesis (69%) in AL amyloidosis. Differences may 
partly be due to the ability of HLC immunoassays to separately identify kappa and lambda 
isotypes of each Ig class, unlike total Ig measurements. An increased frequency of HLC 
suppression was also reported in a study in MGUS, in which 27% and 11% of 999 patients 
displayed immunoparesis as determined by HLC and total Ig measurements, respectively 
(Katzmann, et al 2013). We found no correlation between immunoglobulin suppression and 
NT-proBNP or monoclonal FLC levels, indicating that polyclonal immunoglobulin levels do not 
associate with other risk factors or stage of disease in AL amyloidosis (Sachchithanantham, 
et al 2014). 
Baseline level of dFLC was prognostic in this cohort, as reported previously from other 
studies in AL amyloidosis (Goodman, et al 2005, Palladini, et al 2012)– the absolute value of 
the amyloidogenic protein was directly linked with prognosis. However, in the landmark 
analysis of survivors at six months, the dFLC lacked prognostic power. The biggest challenge 
in AL amyloidosis is early deaths due to disease related complications. Patients surviving 
beyond six months have demonstrated resilience of organ function and have much better 
outcomes (Wechalekar, et al 2013). Baseline biomarkers do not have the same prognostic 
impact on the six month survivors (Wechalekar, et al 2012). The impact of baseline dFLC on 
survivors has (or indeed the lack of prognostic impact of baseline dFLC on survivors as seen 
here), to the best of our knowledge, never been previously reported.  
The striking observation in this series was the impact of severe HLC 
immunoparesis specifically on patients with cardiac involvement in a landmark 
analysis. Cardiac involvement remains the major prognostic determinant in AL patients 
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and risk-adapted strategies have been suggested whereby the aggressiveness of the 
treatment regimen is inversely proportional to the extent of cardiac disease, as 
determined by cardiac biomarkers (Gertz, et al 2004b, Palladini and Merlini 2009, 
Palladini, et al 2009). There is a high likelihood that the gentler regimes are not able to 
achieve a deep clonal response and hence are less efficient in allowing polyclonal 
immunoglobulin recovery – a feature associated with improved outcomes in myeloma 
(Gonzalez-Calle, et al 2017, Harutyunyan, et al 2016, Ludwig, et al 2016, Tovar, et al 
2012); or indeed whether there is higher risk of opportunistic infections or related 
complications contributing to mortality in a compromised cardiovascular patient. In 
this context it would be relevant to assess whether novel therapies, including 
bortezomib and immunomodulatory based regimens, may overcome the adverse effect 
of HLC immunoparesis in cardiac patients (Muchtar, et al 2016b) through more efficient 
targeting of the clone and a boost to polyclonal immune activation (Zamarin, et al 2013). 
By contrast, immunoparesis by total Ig measurement (even severe immunoparesis), 
had no impact on prognosis in this study.  A recent report from the Mayo group showed that 
classical immunoparesis is prognostic in AL amyloidosis (Muchtar, et al 2016a, Muchtar, et al 
2016b). The same group previously reported no association between immunoparesis and 
outcome in a small cohort of 41 AL amyloidosis patients (Muchtar, et al 2016c), intimating that 
sample size may account in part for the discrepant results between studies; and that the 
sensitivity of Hevylite assays may be potentially greater in detecting this effect – the Mayo 
study did not include HLC assessments.  
The impact of immunoparesis in AL patients with renal involvement requires careful 
interpretation, as patients with nephrotic syndrome lose IgG into the urine as a result of 
increased glomerular permeability. In these cases, immunoparesis may reflect IgG loss rather 
than plasma cell suppression (Kaysen and al Bander 1990). Similar to what has been 
described in patients with moderate immunoparesis in other series (Muchtar, et al 2016a) this 
may explain why moderate HLC suppression did not associate with outcome in our patients.  
12 
 
The mechanism of suppression of normal immunoglobulin components in plasma cell 
dyscrasias in AL remains poorly understood but is likely to be directly related to the 
characteristics of the bone marrow plasma cell clone. The group from Salamanca had reported 
that the presence of <5% normal plasma cells defined by multiparameter flow cytometry 
conferred a poor prognosis (Paiva, et al 2011). Similarly, we reported that presence of >10% 
normal plasma cells in the marrow by flow cytometry, irrespective of absolute plasma cell 
percentage by morphology (also a prognostic factor as reported by the Mayo group), predicted 
for better outcomes (Sachachtanatham, et al 2014).  Since normal immunoglobulin production 
is from persisting normal plasma cells in the bone marrow, the suppression of normal 
immunoglobulins as determined by HLC possibly represents the serum manifestation of this 
phenomenon. We are planning a further study of HLC correlating serum findings with baseline 
bone marrow assessments to confirm these observations.   
Whilst this study shows the important prognostic impact of HLC immunoparesis on 
outcomes in AL amyloidosis, the reason for this prognostic impact is far more challenging to 
dissect out.  Infections and worsening heart failure are the commonest causes of serious 
adverse events in patients with AL amyloidosis undergoing chemotherapy (Wechalekar, et al 
2014).  Drugs commonly used in treatment of AL amyloidosis such as dexamethasone or 
cyclophosphamide are excellent immunosuppressive agents, and are likely to eliminate 
normal plasma cells in addition to achieving the desired impact of clonal eradication.  Since 
HLC immunoparesis of the non-clonal uninvolved immunoglobulin is most likely to be directly 
linked to greater suppression/depletion of normal plasma cells, it is tempting to speculate that 
such patients with severe HLC immunoparesis will have worsening immunodeficiency during 
treatment; which could tip these patients into a longer term state of immunodeficiency.  The 
prognostic impact of HLC immunosuppression is greatest soon after completing therapy (i.e. 
in the six month landmark analysis) compared to patients alive at 9 or 12 months, suggesting 
that there might be immune recovery in the survivors; thereby mitigating the prognostic impact 
of immunoparesis.  This immunoparesis may not only predispose to infective complication but 
may be a marker for poorer immune surveillance which may impact the longer term outcomes 
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in plasma cell dyscrasia.  An alternative, or even concurrent, reason may be that the 
suppression of normal plasma cells is direct marker for the aggressiveness of the plasma cell 
clone as impacting on treatment responsiveness and possible persistence of minimal residual 
disease (MRD) with the attendant longer term consequences.  We recently reported the 
persistence of MRD in AL amyloidosis patients in a serological CR (Coyne, et al 2015), 
highlighting the difficulty of eradicating even a small clone.  We hope that an ongoing serial 
study of HLC monitoring in AL patients during and after treatment may address some of these 
questions.     
This study has limitations and these observations need to be validated in a larger 
patient population treated with novel agents. The availability of baseline sera stored at the 
requisite temperatures dictated patient inclusion in this study. Baseline troponin measurement 
was not part of standard patient assessment at the UK NAC at time of this study and hence 
we are unable to present this data. We plan to expand this study to include HLC as part of 
baseline assessments in patients included in our ongoing observational study (ALCHemy) to 
validate these findings in a series of prospectively observed patient cohort. Similarly, the 
retrospective nature of the data limits the ability to assess cause of death and impact, if any, 
of infections due to immunoparesis; particularly worsened after chemotherapy.  
In summary, immunoparesis as defined by HLC suppression and total Ig 
measurements is a relatively common occurrence in AL amyloidosis.  Severe HLC 
immunoparesis appears to be a marker of poor prognosis in patients with cardiac amyloidosis 
and is a particularly powerful marker in survivors beyond the first six months from diagnosis. 
The clinical benefit of routine HLC measurements in patients with AL amyloidosis warrants 
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Figure 1. Survival outcomes in intention-to-treat (ITT) cohort. (A) Median overall survival 
(OS) for the whole cohort (n=163) and (B) for patients stratified by baseline dFLC >180mg/L 
and (C) severe HLC suppression (≥50% suppression in ≥2 Ig isotypes). (D) Median OS for 
patients with cardiac involvement at diagnosis (n=121) and (E) stratified by baseline dFLC 
>180mg/L and (F) severe HLC suppression. Number of patients (deaths) for each arm is 
shown. 
Figure 2. Survival outcomes in 6-month landmark analysis. (A) Median overall survival 
(OS) for patients alive at six months (n=127) and (B) based on baseline dFLC >180mg/L and 
(C) severe HLC suppression (≥50% suppression in ≥2 Ig isotypes). (D) Median OS in the 6-
month landmark analysis for patients with cardiac involvement (n=89) and (E) stratified by 
baseline dFLC >180mg/L and (F) severe HLC suppression. Number of patients (deaths) for 
each arm is shown. 
Figure 3. OS survival for patients with cardiac involvement stratified by baseline risk 
factors (dFLC >180mg/L and severe HLC suppression). In 121 patients with cardiac 
involvement (cardiac disease and/or NT-pro BNP > 332ng/L) presence of none (blue line), 1 
(green line) or 2 (red line) risk factors identified three groups with median survival times of 
35.1, 12.7 and 8.8 months, respectively (p=0.02). Number of patients (deaths) for each arm is 
shown. 
Supplementary Figure 1. Survival outcomes in 9- and 12-month landmark analysis. 
Median OS in the (A) 9-month (n=77) and (B) 12-month (n=68) landmark analysis for patients 
with cardiac involvement and severe HLC suppression (≥50% suppression in ≥2 Ig isotypes). 
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